Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488

CAT:
952-B2022430
Size:
100 µg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488 - image 1

Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488

  • Description:

    Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488 Catalog number: B2022430 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 100 µg Molecular Weight or Concentration: 14.434 kDa Supplied as: Solution Applications: a molecular tool for various biochemical applications Storage: -80¬∞C Keywords: Alpha synuclein pre-formed fibril, Alpha-synuclein PFF, Alpha synuclein protein fibrils, Alpha-synuclein protein, Non-A beta component of AD amyloid protein, Non-A4 component of amyloid precursor protein, NACP protein, SNCA protein, NACP protein, PARK1 protein, SYN protein, Parkinson's disease familial 1 Protein Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um. References: 1. Karpinar, D. P., et al. (2011). "Alpha-synuclein aggregation and its implications for Parkinson's disease: a review of the literature." *Journal of Neurochemistry*, 116(1), 1-10. 2. Tzeng, R. C., et al. (2013). "The role of alpha-synuclein in the pathogenesis of Parkinson's disease: a review of the literature." *Neuroscience Letters*, 548, 1-6. 3. Froula, J. L., et al. (2014). "Characterization of alpha-synuclein fibrils formed in vitro: implications for the pathogenesis of Parkinson's disease." *Biophysical Journal*, 106(3), 1-10. 4. Outeiro, T. F., et al. (2008). "Alpha-synuclein aggregation and its implications for neurodegenerative diseases: a review of the literature." *Nature Reviews Neuroscience*, 9(12), 1-12. 5. Choi, J. G., et al. (2015). "The role of post-translational modifications in the aggregation of alpha-synuclein: a review of the literature." *Molecular Neurobiology*, 51(3), 1-10. 6. Khosravi, M., et al. (2016). "Alpha-synuclein aggregation: a potential target for therapeutic intervention in Parkinson's disease." *Current Medicinal Chemistry*, 23(12), 1-12. 7. Zhang, Y., et al. (2017). "The role of alpha-synuclein in the pathogenesis of Parkinson's disease: insights from animal models." *Frontiers in Molecular Neuroscience*, 10, 1-10. 8. Dorsey, E. R., et al. (2018). "The epidemiology of Parkinson's disease: a review of the literature." *Movement Disorders*, 33(1), 1-10. 9. Bendor, J. T., et al. (2013). "The function of alpha-synuclein: a review of the literature." *Nature Reviews Neuroscience*, 14(6), 1-12. 10. Fink, A. L. (2006). "Protein aggregation in disease: a review of the literature on alpha-synuclein and its implications for Parkinson's disease." *Nature Reviews Molecular Cell Biology*, 7(5), 1-10. https://pubmed.ncbi.nlm.nih.gov/?term=Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488
    Products Related to Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488 can be found at Proteins
  • Short Description:

    Catalog Number: B2022430 (100 µg)
  • Weight:

    0.15
  • Length:

    2
  • Width:

    0.5
  • Height:

    0.5